spacer
home > pmps > winter 2002 > editor's letter
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Editor's Letter

The last 12 months have been something of a roller-coaster ride, with some big 'downs' and a few small 'ups'. Just now, we are in a tunnel waiting to find out what lies ahead. Overshadowing the economic climate post September 11th, there have been spectacular crashes like that of Enron Corp., largely due to voodoo accounting practices. Events such as these are a healthy reminder that leveraging earnings to achieve growth also increases risk. So far, the pharmaceutical industry has seemed immune from similar troubles, while the big merger of Pharmacia and Pfizer looks set to create the first mega-pharma company. M&A deals are pharma's attempt to regain shareholder value. However, the news is grim for employment prospects as the industry braces itself for yet more job losses in the wake of post-merger restructuring.


Earlier in the year, analysts predicted improved prospects for manufacturing which could have helped the production sector in pharma and biotech. Outsourced pharmaceutical manufacturing has proved remarkably resilient. It's as well that the industry has the support of a robust infrastructure enabling it to deliver quality products at costs that are lower than that of in-house manufacturing - as long as similar accounting standards are used to compare them. Is this golden scenario about to change to base metal, to match the leaden skies?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Patricia Lobo, Rebecca Cavalôt
spacer
Dr Patricia Lobo
spacer
spacer
spacer
Rebecca Cavalôt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility

Philadelphia, PA – June 4, 2019 PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

 
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals – gaining strong, new industry contacts and building on existing ones.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement